Technical Analysis for IBIO - iBio, Inc.

Grade Last Price % Change Price Change
grade F 0.8 0.00% 0.00
IBIO closed unchanged on Monday, May 20, 2019, on 38 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical IBIO trend table...

Date Alert Name Type % Chg
Inside Day Range Contraction 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Fell Below 200 DMA Bearish 0.00%
New Downtrend Bearish 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Crossed Above 200 DMA Bullish -2.44%
Lower Bollinger Band Touch Weakness -2.44%
200 DMA Resistance Bearish -0.11%
MACD Bearish Centerline Cross Bearish -0.11%
Outside Day Range Expansion -0.11%

Older signals for IBIO ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

iBio, Inc., a biotechnology company, engages in the development and commercialization of vaccines and therapeutic proteins through its proprietary iBioLaunch platform technology in the United States. Its product portfolio includes seasonal and H1N1 influenza vaccines for the seasonal influenza virus strains; pandemic avian influenza vaccine for the pathogenic avian influenza viruses; and therapeutic vaccines for human papilloma virus. The company also offers biodefense products, including oral anthrax booster vaccine candidates and candidate plague vaccines. In addition, it provides therapeutic protein product candidates comprising human alpha-galactosidase A for the treatment of Fabry disease; human C-1 esterase inhibitor for the treatment of hereditary angioedema; and human alpha-1 antitrypsin for treatment of disorders caused by a deficiency of alpha-1 antitrypsin. Further, the company offers vaccine enhancements through its iBioModulator platform. It has a license and collaboration agreement with Caliber Biotherapeutics, LLC for the development and production of recombinant plant-based biopharmaceuticals. The company is headquartered in Newark, Delaware.
Medicine Biotechnology Disorders Influenza Vaccination Microbiology Vaccines Biopharmaceuticals Hereditary Angioedema Seasonal Influenza Deficiency Fabry Disease H5n1 Clinical Trials Human Papilloma Virus Influenza Vaccines Treatment Of Fabry Disease
Is IBIO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 1.72
52 Week Low 0.495
Average Volume 56,535
200-Day Moving Average 0.8159
50-Day Moving Average 0.8423
20-Day Moving Average 0.8413
10-Day Moving Average 0.8374
Average True Range 0.0661
ADX 26.77
+DI 7.0378
-DI 19.1892
Chandelier Exit (Long, 3 ATRs ) 0.7317
Chandelier Exit (Short, 3 ATRs ) 0.9483
Upper Bollinger Band 0.9152
Lower Bollinger Band 0.7674
Percent B (%b) 0.22
BandWidth 17.568049
MACD Line -0.0083
MACD Signal Line -0.0012
MACD Histogram -0.0072
Fundamentals Value
Market Cap 74.25 Million
Num Shares 92.8 Million
EPS -0.16
Price-to-Earnings (P/E) Ratio -4.88
Price-to-Sales 74.56
Price-to-Book 3.17
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.87
Resistance 3 (R3) 0.86 0.84 0.86
Resistance 2 (R2) 0.84 0.82 0.84 0.85
Resistance 1 (R1) 0.82 0.81 0.83 0.82 0.85
Pivot Point 0.79 0.79 0.80 0.79 0.79
Support 1 (S1) 0.77 0.77 0.78 0.78 0.75
Support 2 (S2) 0.75 0.76 0.75 0.75
Support 3 (S3) 0.73 0.75 0.74
Support 4 (S4) 0.73